Some interferon beta (IFNβ)-treated patients with multiple sclerosis develop antibody-mediated decreased bioactivity with resultant loss of therapeutic effect. The authors developed realtime multiplex reverse transcr...Some interferon beta (IFNβ)-treated patients with multiple sclerosis develop antibody-mediated decreased bioactivity with resultant loss of therapeutic effect. The authors developed realtime multiplex reverse transcriptase PCR to measure expression of three IFNβ-inducible genes to directly assess IFNβbioactivity in patients with neutralizing antibodies (NAbs). The three genes responded in tandem. Correlation of NAb level with bioactivity at low/ moderate NAb levels was poor, indicating that for such patients, direct measurement of IFNβbioactivity is most reliable.展开更多
文摘Some interferon beta (IFNβ)-treated patients with multiple sclerosis develop antibody-mediated decreased bioactivity with resultant loss of therapeutic effect. The authors developed realtime multiplex reverse transcriptase PCR to measure expression of three IFNβ-inducible genes to directly assess IFNβbioactivity in patients with neutralizing antibodies (NAbs). The three genes responded in tandem. Correlation of NAb level with bioactivity at low/ moderate NAb levels was poor, indicating that for such patients, direct measurement of IFNβbioactivity is most reliable.
